

**Research Journal Publications by LTR Staff Members**  
*LTR staff members are indicated in italic type.*

**Research Journal Publications—Published in 2014**

1. Altekruse SF, Dickie L, *Wu X-C*, *Hsieh M-C*, Wu M, Lee R, and Delacroix S, **Clinical and prognostic factors for renal parenchymal, pelvis, and ureter cancers in SEER registries: Collaborative stage data collection system, version 2.** *Cancer*, 2014. 120: p. 3826-3835.
2. Anderson RT, Morris CR, Kimmick G, Trentham-Dietz A, Camacho F, *Wu XC*, Sabatino SA, Fleming ST, and Lipscomb J, **Patterns of locoregional treatment for nonmetastatic breast cancer by patient and health system factors.** *Cancer*, 2014.
3. Bensen JT, Xu Z, McKeigue PM, Smith GJ, *Fontham ET*, Mohler JL, and Taylor JA, **Admixturemapping of prostate cancer in African Americans participating in the North Carolina-Louisiana Prostate Cancer Project (PCaP).** *Prostate*, 2014. 74(1): p. 1-9.
4. *Chen VW*, Ehemann CR, Johnson CJ, Hernandez MN, Rousseau D, Styles TS, West DW, *Hsieh M*, Hakenewerth AM, Celaya MO, Rycroft RK, Wike JM, Pearson M, Brockhouse J, Mulvihill LG, and Zhang KB, **Enhancing Cancer Registry Data for Comparative Effectiveness Research (CER) Project: Overview and Methodology.** *J Registry Manag*, 2014. 41(3): p. 103-12.
5. *Chen VW*, *Hsieh MC*, Charlton ME, *Ruiz BA*, Karlitz J, Altekruse SF, Ries LA, and Jessup JM, **Analysis of stage and clinical/prognostic factors for colon and rectal cancer from SEER registries: AJCC and collaborative stage data collection system.** *Cancer*, 2014. 120 Suppl 23: p. 3793-806.
6. *Chen VW*, *Ruiz BA*, *Hsieh MC*, *Wu XC*, Ries LA, and Lewis DR, **Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system.** *Cancer*, 2014. 120 Suppl 23: p. 3781-92.
7. Flagg EW, Datta SD, Saraiya M, Unger ER, *Peters E*, *Cole L*, *Chen VW*, Tucker T, Byrne MJ, Copeland G, Silva W, Watson M, and Weinstock H, **Population-based surveillance**

**for cervical cancer precursors in three central cancer registries, United States 2009.** *Cancer Causes Control*, 2014. 25(5): p. 571-81.

8. Hamilton AS, Fleming ST, Wang D, Goodman M, Wu XC, Owen JB, Lo M, Ho A, Anderson RT, and Thompson T, **Clinical and Demographic Factors Associated With Receipt of Non Guidelineconcordant Initial Therapy for Nonmetastatic Prostate Cancer.** *Am J Clin Oncol*, 2014.
9. Hernandez BY, Goodman MT, Unger ER, Steinau M, Powers A, Lynch CF, Cozen W, Saber MS, Peters ES, Wilkinson EJ, Copeland G, Hopenhayn C, Huang Y, Watson M, Altekruse SF, Lyu C, and Saraiya M, **Human papillomavirus genotype prevalence in invasive penile cancers from a registry-based United States population.** *Front Oncol*, 2014. 4: p. 9.
10. Hopenhayn C, Christian A, Christian WJ, Watson M, Unger ER, Lynch CF, Peters ES, Wilkinson EJ, Huang Y, Copeland G, Cozen W, Saber MS, Goodman MT, Hernandez BY, Steinau M, Lyu C, Tucker TT, and Saraiya M, **Prevalence of human papillomavirus types in invasive cervical cancers from 7 US cancer registries before vaccine introduction.** *J Low Genit Tract Dis*, 2014. 18(2): p. 182-9.
11. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, and Cronin KA, **US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.** *J Natl Cancer Inst*, 2014. 106(5).
12. Howlader N, Chen VW, Ries LA, Loch MM, Lee R, DeSantis C, Lin CC, Ruhl J, and Cronin KA, **Overview of breast cancer collaborative stage data items--their definitions, quality, usage, and clinical implications: a review of SEER data for 2004-2010.** *Cancer*, 2014. 120 Suppl 23: p. 3771-80.
13. Karlitz JJ, Blanton C, Andrews P, Chen VW, Wu XC, and Fontham E, **Colorectal Cancer Incidence Rates in the Louisiana Acadian Parishes Demonstrated to be Among the Highest in the United States.** *Clin Transl Gastroenterol*, 2014. 5: p. e60.
14. Keegan TH, Tao L, DeRouen MC, Wu XC, Prasad P, Lynch CF, Shnorhavorian M, Zebrack BJ, Chu R, Harlan LC, Smith AW, and Parsons HM, **Medical care in adolescents and young adult cancer survivors: what are the biggest access-related barriers?** *J Cancer Surviv*, 2014. 8(2): p. 282-92.

15. Kimmick G, Fleming ST, Sabatino SA, Wu XC, Hwang W, Wilson JF, Lund MJ, Cress R, and Anderson RT, **Comorbidity burden and guideline-concordant care for breast cancer.** *J Am Geriatr Soc*, 2014. 62(3): p. 482-8.
16. Potosky AL, Harlan LC, Albritton K, Cress RD, Friedman DL, Hamilton AS, Kato I, Keegan TH, Keel G, Schwartz SM, Seibel NL, Shnorhavorian M, West MM, and Wu XC, **Use of appropriate initial treatment among adolescents and young adults with cancer.** *J Natl Cancer Inst*, 2014. 106(11).
17. Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Chen VW, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Koyama T, and Penson DF, **Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment.** *Cancer*, 2014. 120(8): p. 1263-71.
18. Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Koyama T, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, McCollum D, Paddock LE, Stanford JL, Stroup AM, Wu XC, and Penson DF, **The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research.** *Eur Urol*, 2014.
19. Sinno AK, Saraiya M, Thompson TD, Hernandez BY, Goodman MT, Steinau M, Lynch CF, Cozen W, Saber MS, Peters ES, Wilkinson EJ, Copeland G, Hopenhayn C, Watson M, Lyu C, and Unger ER, **Human papillomavirus genotype prevalence in invasive vaginal cancer from a registrybased population.** *Obstet Gynecol*, 2014. 123(4): p. 817-21.
20. Steinau M, Saraiya M, Goodman MT, Peters ES, Watson M, Cleveland JL, Lynch CF, Wilkinson EJ, Hernandez BY, Copeland G, Saber MS, Hopenhayn C, Huang Y, Cozen W, Lyu C, and Unger ER, **Human papillomavirus prevalence in oropharyngeal cancer before vaccine introduction, United States.** *Emerg Infect Dis*, 2014. 20(5): p. 822-8.
21. Wang D, Ho A, Hamilton AS, Wu XC, Lo M, Fleming S, Goodman M, Thompson T, and Owen J, **Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer.** *Radiat Oncol*, 2014. 9: p. 47.

22. Yu Q, Fan Y, and Wu X, **General Multiple Mediation Analysis With an Application to Explore Racial Disparities in Breast Cancer Survival.** *J Biomet Biostat*, 2014. 5(189): p. 2.
23. Zhao W, Guan J, Horswell R, Li W, Wang Y, Wu X, and Hu G, **HDL cholesterol and cancer risk among patients with type 2 diabetes.** *Diabetes Care*, 2014. 37(12): p. 3196-203.
24. Fleming ST, Hamilton AS, Sabatino SA, Kimmick GG, Wu X-C, Owen JB, et al. **Treatment patterns for prostate cancer: comparison of Medicare claims data to medical record review.** *Medical care*. 2014;52(9):e58-e64.
25. Bosetti C, Rosato V, Li D, Silverman D, Petersen GM, Petersen GM, Bracci PM, Neale RE, Muscat J, Anderson K, Gallinger S, Olson SH, Miller AB, Bas Bueno-de-Mesquita H, Scelo G, Janout V, Holcatova I, Laggiou P, Serraino D, Lucenteforte E, Fabianova E, Ghadirian P, Baghurst PA, Zatonski W, Foretova L, *Fontham E*, Bamlet WR, Holly EA, Negri E, Hassan M, Prizment A, Cotterchio M, Cleary S, Kurtz RC, Maisonneuve P, Trichopoulos D, Polesel J, Duell EJ, Boffetta P, La Vecchia C. **Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium.** *Ann Oncol*, 2014. 25(10): p. 2065-2072.
26. Song L, Weaver MA, Chen RC, Bensen JT, *Fontham E*, Mohler JL, Mishel M, Godley PA, Sleath B. **Associations between patient-provider communication and socio-cultural factors in prostate cancer patients: a cross-sectional evaluation of racial differences.** *Patient Educ Couns*, 2014. 97(3):339-46.
27. Su LJ, *Fontham ET*. **Prostate cancer: an occupational hazard?** *Future Oncol*, 2014. 10(6):903-6.